Drugs in MeSH Category Respiratory System Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	DOPRAM	doxapram hydrochloride	INJECTABLE;INJECTION	014879-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Watson Labs	DOXAPRAM HYDROCHLORIDE	doxapram hydrochloride	INJECTABLE;INJECTION	073529-001	Jan 30, 1992		DISCN	No	No
Chartwell Injectable	DOXAPRAM HYDROCHLORIDE	doxapram hydrochloride	INJECTABLE;INJECTION	076266-001	Jan 10, 2003	AP	RX	No	No

Last updated: July 28, 2026

Market dynamics and patent landscape for NLM MeSH “Respiratory System Agents”: who is blocked, who is launching, and where exclusivity breaks

Respiratory System Agents span multiple high-sales therapeutic classes (inhaled corticosteroids, LABA/LAMA bronchodilators, fixed-dose combinations, biologics for severe asthma, and treatments for COPD, cystic fibrosis, and pulmonary arterial hypertension). Patent and regulatory timing differs by molecule and delivery system, with exclusivity most often extended by reformulation (device and particle engineering), new fixed-dose combinations, and method-of-use claims rather than by primary API patents alone. Across this MeSH class, competitive pressure concentrates where (1) Orange Book listings show long tails of formulation or use patents, but (2) the regulatory pathway allows early ANDA readiness or (3) pay-for-delay settlements or authorized generics shift near-term generic entry risk.

Bottom line for business decisions: map market exposure by specific active ingredient + dosage form/device (not just indication), then reconcile Orange Book patent sets with FDA exclusivity (NCE/505(b)(2)/3-year and 5-year exclusivity plus pediatric exclusivity where applicable) and planned Paragraph IV windows. For biologics and biosimilars, the blocking set is typically less about Orange Book and more about biologic-specific patent estates, BLA reference product exclusivity, and jurisdictional enforcement posture.

---

What patents protect respiratory system drugs (MeSH Respiratory System Agents), and how are they structured?

Answer: Patent estates in Respiratory System Agents cluster into four buckets: (1) composition-of-matter for the active ingredient, (2) inhalation-specific formulations and particles (micronized/engineered distributions, suspension vs solution, lactose blending, excipient systems), (3) device-and-delivery patents (inhaler mechanisms, dose counters, reservoirs, spurious emission controls), and (4) method-of-use patents (maintenance regimens, asthma phenotypes, COPD exacerbation reduction, combinations with specific titration steps). Combination products add separate claims for the fixed-dose ratio, particle co-mingling, and clinical utility for distinct endpoints.

How “inhalation formulation” patents extend exclusivity without changing the API

Inhaled products frequently retain market exclusivity through secondary patents covering:

• particle size distribution and aerodynamic properties for lung deposition
• suspension stability for nebulizers
• preservative-free excipient systems
• device compatibility requirements (force needed to aerosolize, valve geometry, mouthpiece flow profiles)
• dose uniformity and metering tolerances

Practical implication: an ANDA that uses the same API but different formulation/device can still face infringement risk if Orange Book lists formulation/device patents that are tied to the same product claim scope.

What “method-of-use” claims do in asthma and COPD

Method-of-use claims often target:

• exacerbation reduction in defined patient subgroups
• step-up or maintenance regimens tied to specific endpoints
• treatment of steroid-resistant asthma patterns or exacerbation-prone phenotypes
• duration or sequencing (initiation, add-on timing)

Practical implication: even when generic composition patents are designed around, use claims can still block launch, especially when labels and clinical endpoints remain close to the patented use.

Who holds the typical estates in respiratory (assignees and funding patterns)

Estate owners are concentrated in:

• originator pharma with inhalation platforms (frequently owning multiple generations of inhaler devices and reformulations)
• biologic developers with immune-target IP estates (often layered across multiple mechanisms of action, e.g., IL-4/IL-13 axis in asthma)
• large inhalation device suppliers via licensing arrangements (device patents sometimes show as assignees different from the drug company)

Commercial implication: licensing and settlement leverage often sits with the combination product platform owner because it controls both the labeled regimen and the core formulation/device claims.

---

Which Respiratory System Agents drugs have the most active patent blocking sets for generics?

Answer: The highest blocking sets tend to be for fixed-dose inhaled combinations and branded nebulized or pressurized products where Orange Book lists many patents tied to formulation and use. The “generic bottleneck” is usually the ability to produce a bioequivalent aerosol performance profile and avoid infringement of formulation/device claims.

Combination inhalers: where patent density is typically highest

Fixed-dose ICS/LABA and LAMA/LABA combinations usually produce:

• multiple ratios and particle engineering claims
• device-specific metering patents
• separate use claims for exacerbation and symptom control endpoints

Generic risk pattern: ANDA sponsors must align not only with API and strength but also with inhalation performance attributes linked to claim scope. Even if the API is off-patent, formulation and use patents can delay a practical launch.

Oral small molecules in respiratory: when blocking sets simplify

For some oral respiratory drugs (e.g., certain anti-inflammatory or anti-infective agents used in chronic lung disease contexts), primary API patents can dominate. Once those expire and exclusivity periods end, generic entry risk often declines faster than in inhalation products.

Generic risk pattern: fewer device-linked claims generally reduce the “reformulation trap.”

---

When do branded respiratory exclusivities and patent expirations create generic entry windows?

Answer: In most respiratory assets, generic entry timing is controlled by the later of: (1) expiration of the last relevant Orange Book-listed patent for the specific listed dosage form/device, or (2) the end of regulatory exclusivity (including pediatric exclusivity) that bars full approval, and (3) any settlement-based “launch design” provisions.

Typical timelines that matter for launch planning

• Patent expiration (last Orange Book listed patent): determines the earliest date of legally safe generic marketing if no Paragraph IV succeeds early.
• Regulatory exclusivity:
  • NCE exclusivity (where applicable) blocks approval for the reference product.
  • 5-year exclusivity can apply to new clinical investigations supporting approval of a new product or new indication under 505(b)(2).
  • 3-year exclusivity can extend approval if the application contains new clinical studies.
  • Pediatric exclusivity can tack on 6 months to patent term or exclusivity (depending on the basis).
• Paragraph IV litigation clock: filing a Paragraph IV triggers a 30-month stay if certain conditions are met; resolution timing can shorten or extend the path to approval.

Practical implication: the most actionable date for forecasting is “earliest legally marketable date” derived from (i) Orange Book last patent expiry, (ii) exclusivity ending dates, and (iii) settlement triggers.

How to forecast “real-world” entry in inhalation

Even after legal readiness, commercial entry depends on:

• inhaler device supply constraints
• willingness to launch with a potentially lower rebate package
• payor switching cycles
• product differentiation strategies (form factor, dose counter, ease of use)

---

What Paragraph IV challenges are most common in respiratory system agents?

Answer: Paragraph IV challenges concentrate in:

• inhaled combination products with dense formulation and use patents
• reformulated versions that have separate Orange Book listings from the original product
• “same active, different delivery” products where claim coverage differs by device

What generic challengers usually certify against

For each Orange Book-listed patent, generic applicants must certify as:

• Paragraph I: patent not listed in Orange Book or not filed for the relevant reference
• Paragraph II: patent expired
• Paragraph III: patent expiration date known, no earlier than
• Paragraph IV: patent alleged invalid or not infringed

Practical implication: in respiratory inhalers, Paragraph IV certifications often target the most recent formulation/device/use patents rather than the core API.

Who wins and why it matters

When originators defend successfully, generic launch often shifts beyond the originally targeted window. When originators settle, entry can shift to:

• later “designated date” launches
• limited authorized generic arrangements
• scope-limited label designs

---

How does biosimilar risk compare with generic risk in asthma biologics and COPD therapies?

Answer: Biosimilar risk is typically anchored to biologic-specific reference product exclusivity and a different patent landscape than small molecules. Orange Book is less central; BLA reference product exclusivity and biologic patent estates dominate.

What blocks biosimilars most often

• patents covering the biologic molecule and variants
• patents covering manufacturing and analytical methods
• patents covering dosing regimens and patient selection endpoints (less common than for small molecules but still present)

Settlement dynamics

Biosimilar settlements can occur via:

• “carve-out” arrangements in which launch timing is negotiated by patent category
• authorized biosimilar product supply with specific launch triggers

---

What is the Orange Book status of major Respiratory System Agents products?

Answer: Orange Book status is product- and strength-specific and must be read at the exact NDA level and dosage form/device listing. For respiratory, the most decision-relevant items are:

• the count of listed patents per NDA
• which patents are likely “relevant” to infringement for a proposed generic formulation/device
• expiration dates and any pediatric exclusivity effects

Operational rule: in forecasting and litigation risk, treat each NDA dosage form as a separate asset because formulations and devices can have distinct patent lists even when the API is the same.

---

How many patents cover inhaled corticosteroid/LABA and LAMA/LABA combination products, and what are the expiration drivers?

Answer: Patent density is usually highest for fixed-dose combination inhalers due to layering of:

• core API patents
• formulation and particle patents for the co-delivery ratio
• device metering and dose control patents
• use claims tied to specific endpoints

Expiration drivers that most often delay generic or biosimilar competition

• late-expiring formulation/device patents
• additional-use patents with broad claim scope
• pediatric exclusivity extending the practical earliest approval date

Commercial implication: even when primary API patents expire, “late layer” patents can keep payors and patients locked to branded inhalers longer than expected based on API expiration alone.

---

What formulations are protected by patents in respiratory drugs: dry powder vs metered-dose vs nebulized?

Answer: Patents protect formulation performance properties differently by delivery system.

Dry powder inhalers (DPI)

Common formulation protection themes include:

• carrier blend ratios and aerodynamic particle distributions
• moisture control excipient engineering
• flow properties affecting dose dispersibility

Generic risk: a DPI generic must match aerosol performance characteristics within claim-linked tolerances.

Metered-dose inhalers (MDI)

Common formulation protection themes include:

• propellant-excipient interactions
• suspension stability and uniformity
• valve and actuator compatibility constraints

Generic risk: even small differences in plume characteristics can raise infringement or performance and approval risk.

Nebulized solutions

Common protection themes include:

• preservative-free or preservative-specific excipient systems
• stability and shelf-life profiles
• container closure system constraints

Generic risk: “same solution, different container” can still trigger device/container patents in some estates.

---

What patent litigation affects respiratory system agent commercialization?

Answer: Litigation in respiratory typically centers on infringement of inhalation formulation, device, and method-of-use patents tied to Orange Book-listed products, with the most consequential cases being those that determine whether challengers can launch before the last blocking layer expires.

Litigation outcomes that change market structure

• wins or settlements that allow an earlier-than-origins estimate launch date for a generic challenger
• outcomes that narrow claim scope and allow “design around” formulations
• settlement agreements that delay entry but preserve originator switching or rebate leverage

---

How do settlement agreements and authorized generics change near-term respiratory competition?

Answer: Settlements often convert a high-uncertainty patent dispute into a predictable launch schedule. Authorized generic deals can extend branded revenue by capturing some of the generic market while avoiding the long-term price erosion risk.

What to look for in settlement structure (in respiratory)

• designated launch dates tied to patent expiry or specific certifications
• market allocation rules (who sells, when, at what timing)
• label carve-outs that limit which indications a generic can claim
• supply agreements and distribution commitments

Commercial implication: even if a generic receives approval, labeling and contractual terms can delay broader uptake or restrict substitution.

---

Which companies are challenging respiratory drug patents via Paragraph IV, and how does that shape pricing?

Answer: Challenges tend to come from a small set of generic and biosimilar companies with active respiratory portfolios. Their strategies concentrate on:

• attacking the most recent formulation/use patents
• filing multiple ANDAs to create a portfolio of entry options
• leveraging settlement leverage by demonstrating manufacturing readiness and a credible infringement design-around

Pricing implication: successful early entry tends to compress the branded price premium; unsuccessful challenges delay that and maintain higher branded net pricing.

---

How does the competitive landscape differ between COPD, asthma, cystic fibrosis, pulmonary hypertension, and lung infection?

Answer: The competitive geometry is driven by biology, endpoints, and delivery.

COPD

• heavy reliance on inhaled bronchodilator classes
• combination inhalers drive most patent and generic risk
• exacerbation endpoint method-of-use claims can be important

Asthma

• inhaled combinations plus biologics for severe disease
• higher role for phenotype and dosing regimen differentiation in IP
• biosimilar risk differs structurally from ANDA risk

Cystic fibrosis

• combination therapies and modulators produce different patent layering
• real-world switching hinges on genotype alignment and payer formularies

Pulmonary arterial hypertension (PAH)

• oral agents and inhaled therapies can show different patent density patterns
• device and formulation patents can matter for inhaled routes

Lung infection and anti-inflammatory respiratory agents

• antibiotics and inhaled anti-infectives shift patent blocking patterns toward primary API and manufacturing process claims

---

Revenue exposure: where most branded respiratory income sits relative to patent cliffs

Answer: Branded revenue exposure is usually concentrated in:

• flagship inhaled combination products with large payer coverage and frequent refill cycles
• biologic products with high net pricing and restricted interchangeability
• niche-but-high-cost therapies for severe asthma phenotypes and advanced COPD exacerbation prevention

Forecast logic: the most exposed assets are those where the last blocking patents expire within a 12-36 month window and where Paragraph IV challengers have already filed, signaling either design-around feasibility or expected settlement.

---

Key Takeaways

• Respiratory System Agents IP is layered: API patents are often not the last barrier; inhalation formulation, device delivery, and method-of-use claims extend exclusivity and raise generic design-around risk.
• The most actionable forecast input is NDA-specific Orange Book patent sets combined with FDA exclusivity and Paragraph IV timing, not API expiry alone.
• Fixed-dose inhaled combinations typically carry the densest patent blocking sets, making litigation and settlement outcomes central to near-term market structure.
• Biosimilar competition for respiratory biologics follows biologic-specific exclusivity and patent estates, with risk concentrated in molecule, manufacturing, and dosing/regimen-related patents rather than inhaler-device formulations.
• Revenue cliffs concentrate in products with large inhaled volumes and multiple late-expiring patents; competitive entry often shifts based on the resolution of formulation and use patent disputes.

---

FAQs

1) How do inhaler device patents affect ANDA approval risk for respiratory drugs?

Device-linked patents can create infringement risk even if the formulation matches the API and strength, especially when claims cover metering, dose control, or delivery mechanics aligned to branded performance attributes.

2) What is the typical claim scope difference between formulation patents for DPI vs MDI respiratory products?

DPI estates more often claim carrier blend composition and aerosolization behavior, while MDI estates more often claim suspension stability, excipient-propellant interactions, and actuator compatibility.

3) When should a generic plan a Paragraph IV filing in COPD combination inhalers?

When the last relevant Orange Book formulation/use/device patents are targeted for a credible invalidity or non-infringement theory and when regulatory exclusivity is either expired or can be navigated via the applicant’s pathway timing.

4) How do pediatric exclusivity effects change respiratory generic entry forecasts?

Pediatric exclusivity can extend the effective exclusivity/approval timeline by six months, shifting both litigation stay economics and the earliest legally marketable launch date.

5) What settlement terms most often delay respiratory generic launches even after approval?

Launch date provisions tied to patent expiry, label carve-outs, and authorized generic arrangements that preserve branded market share can delay broader uptake and substitution despite regulatory approval.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Guidance for Industry: Paragraph IV Certifications and Patent Litigation. U.S. Food and Drug Administration.
3. USPTO. Patent term and PTA basics (as applicable to FDA-regulated products). United States Patent and Trademark Office.